Annovis Bio discloses preliminary cash of $2.8 million as of September 30, 2026

Annovis Bio, Inc. filed a Form 8-K dated November 4, 2026, disclosing a preliminary estimate of its cash position for the end of the third quarter. The company estimated that its cash and cash equivalents totaled approximately $2.8 million as of September 30, 2026.¹

The filing does not include any updates on clinical trials, regulatory filings, or pipeline timelines. Its sole disclosed content under Item 2.02 is the cash estimate.

Annovis Bio cautioned that the figure is not final. The company's interim financial statements for the three and nine months ended September 30, 2026 were not yet available, and the quarterly financial closing process for that period had not been completed.¹ As a result, the disclosed cash figure reflects preliminary, unaudited information that is subject to change.¹

The company further noted that actual results may differ from these estimates once financial closing procedures, adjustments, and management review are complete, and that results for the period are not necessarily indicative of any future period.¹

Annovis Bio said the preliminary cash estimates were prepared by and remain the responsibility of company management, and that its independent registered public accounting firm has not reviewed or expressed any assurance on the figures.¹

The filing was signed by Maria Maccecchini, the company's Chief Executive Officer. The report is dated November 4, 2026.¹ The 8-K does not state a cash runway figure or provide guidance on future financing plans.